

AstraZeneca



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/509941	First Named Inventor: Elaine Sophie Elizabeth Stokes
371 Filing Date: 10/01/2004	Attorney Docket No.: 100690-1P US
Examiner: Johnson, Jason H	Group Art Unit : 1624
Customer No.: 44992	Confirmation No.: 4973
Title: Benzamide Derivatives Useful As Histone Deacetylase Inhibitors	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 08/08/2006

Signature
Elizabeth Chevreveski

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56. A machine translation into English of Items 12-20 on the SB08A Form under Foreign Patent documents are also being provided herewith for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

113277 U.S. PTO
10/509941



081406

REMARKS


In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application; or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application


Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 503231, referencing Attorney Docket No. 100690-1P US.

Respectfully submitted,



Name: Carol A. Loeschorn
Dated: 08/08/2006
Reg. No.: 35590
Phone No.: 781-839-4000
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451

Enclosures: Form SB08A
28 References and 9 Machine Translations



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10509941
	Filing Date		2004-10-01
	First Named Inventor	Elaine Sophie Elizabeth Stokes	
	Art Unit	1624	
	Examiner Name	Johnson, Jason H	
	Attorney Docket Number	100690-1P US	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3974172		1976-08-10	Sahm, et al.	
	2	3931215		1976-01-06	Horn, et al.	
	3	6174905	B1	2001-01-16	Suzuki, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040087631	A1	2004-05-06	Bacopoulos, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0847992	EP	A1	1998-06-17	Mitsui Chemicals, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10509941
Filing Date		2004-10-01
First Named Inventor	Elaine Sophie Elizabeth Stokes	
Art Unit	1624	
Examiner Name	Johnson, Jason H	
Attorney Docket Number	100690-1P US	

2	03/075839	WO	A2	2003-09-18	Aton Pharma, Inc.	<input type="checkbox"/>
3	03/075856	WO	A2	2003-09-18	University of Delaware	<input type="checkbox"/>
4	03/076400	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.	<input type="checkbox"/>
5	03/076401	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.	<input type="checkbox"/>
6	03/076430	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.	<input type="checkbox"/>
7	03/076421	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.	<input type="checkbox"/>
8	03/076422	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.	<input type="checkbox"/>
9	03/076438	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.	<input type="checkbox"/>
10	01/38322	WO	A1	2001-05-31	Methylgene, Inc.	<input type="checkbox"/>
11	03/024448	WO	A2	2003-03-27	Methylgene, Inc.	<input type="checkbox"/>
12	01/74791	WO	A1	2001-10-11	Yamanouchi Pharmaceutical Co., LTD	<input checked="" type="checkbox"/>



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10509941
Filing Date		2004-10-01
First Named Inventor	Elaine Sophie Elizabeth Stokes	
Art Unit	1624	
Examiner Name	Johnson, Jason H	
Attorney Docket Number	100690-1P US	

	13	03/076395	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.		<input type="checkbox"/>
	14	03/075929	WO	A1	2003-09-18	Janssen Pharmaceutica N.V.		<input type="checkbox"/>
	15	11-269140	JP	A	1999-10-05	Mitsui Chem, Inc.		<input checked="" type="checkbox"/>
	16	10-152462	JP	A	1998-06-09	Mitsui Chem, Inc.		<input checked="" type="checkbox"/>
	17	11-269146	JP	A	1999-10-05	Mitsui Chem, Inc.		<input checked="" type="checkbox"/>
	18	11-335375	JP	A	1999-12-07	Mitsui Chem, Inc.		<input checked="" type="checkbox"/>
	19	11-302173	JP	A	1999-11-02	Mitsui Chem, Inc.		<input checked="" type="checkbox"/>
	20	2000-302765	JP	A	2000-10-31	Yamanouchi Pharmaceut. Co. LTD		<input checked="" type="checkbox"/>
	21	2002-161084	JP	A	2002-06-04	Sumitomo Pharmaceut. Co. LTD		<input checked="" type="checkbox"/>
	22	05-239069	JP	A	1993-09-17	Canon, INC		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10509941
Filing Date	2004-10-01
First Named Inventor	Elaine Sophie Elizabeth Stokes
Art Unit	1624
Examiner Name	Johnson, Jason H
Attorney Docket Number	100690-1P US

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Yamada et al. Preparation of benzothiazole and Benzoxazole derivatives and analogs as liquid crystals. XP-002248768, 1994:522228 CAPLUS, Abstract	<input type="checkbox"/>
	2	Koshio, et al. Preparation of phenyldiazepane derivatives or salt thereof having anticoagulant activity. XP-002248767, 2000:765431 CAPLUS, Abstract	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10509941
Filing Date	2004-10-01
First Named Inventor	Elaine Sophie Elizabeth Stokes
Art Unit	1624
Examiner Name	Johnson, Jason H
Attorney Docket Number	100690-1P US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).


☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2006-08-08
Name/Print	Carol A. Loeschorn	Registration Number	35590

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

AN - 1994:522228 CAPLUS

XP-002248768

DN - 121:122228

TI - Preparation of benzothiazole and benzoxazole derivatives and analogs as liquid crystals

IN - Yamada, Yoko; Takiguchi, Takao; Iwaki, Takashi; Tokano, Goji; Nakamura, Shinichi

PA - Canon Kk, Japan

SO - Jpn. Kokai Tokkyo Koho, 64 pp.

CODEN: JKXXAF

DT - Patent

LA - Japanese

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PN - JP5239869 A 19930917 JP 1992-75987 19920228

PR - JP 1992-75987 19920228

OS - MARPAT 121:122228

AB - The title compds. (Markush structure given) are prepd. A mixt. of phenol deriv. I and p-toluenesulfonic acid in 1,2-dichlorobenzene was stirred at 190 - 202.degree. for 50 min to give, after workup, II. The title liq. crystals show high response speeds.


IT - ---156932-97-7P---

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of liq. crystal)

RN - 156932-97-7 CAPLUS

CN - Benzamide, 4-(5-hexyl-1,3,2-dioxaborinan-2-yl)-N-(5-hexyl-2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



Page 1-A

.....Me

Page 1-B


XP-002248767

AN - 2880:765431 CAPLUS
 DN - 133:321906
 TI - Preparation of phenyldiazepane derivatives or salt thereof having anticoagulant activity
 IN - Koshio, Hiroyuki; Hirayama, Fukushi; Seki, Morio; Ishihara, Tsukasa; Kanzawa, Keizo; Hachiya, Shunichiro; Taniuchi, Yuta; Matsumoto, Yuzo
 PA - Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO - Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DT - Patent
 LA - Japanese
 FAN.CNT 1

P.D.	00-00-00	2
P.	1-2	

PATENT NO. KIND DATE APPLICATION NO. DATE

PN - JP2000302765 A 20001031 JP 1999-117025 19990423
 PR - JP 1999-117025 19990423
 OS - MARPAT 133:321906
 AB - The title compds. (I; ring A = aryl or heteroaryl optionally having 1-3 substituents; B1 = CO, NR3, NR3CO; B2 = CO, NR4, NR4CO; R1 - R4 = H, lower alkyl) or salts thereof are prep'd. as inhibitors of activated blood coagulation factor X which are useful as blood coagulation inhibitors or for the treatment or prevention of diseases caused by thrombosis or embolism (no data). Thus, chlorination of 4-(4-methyl-1,4-diazepan-1-yl)benzoic acid hydrochloride with SOCl2 at 60.degree. for 90 min gave 4-(4-methyl-1,4-diazepan-1-yl)benzoyl chloride which was condensed with 2'-amino-3-cyanobenzanilide in pyridine at room temp. for 2 h to give N-(3-cyanobenzoyl)-N'-(4-(4-methyl-1,4-diazepan-1-yl)benzoyl)-1,2-phenylenediamine.
 IT - ---303134-06-7P--- ---303134-17-0P--- ---303134-59-0P---
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of phenyldiazepane derivs. or salt thereof having anticoagulant activity as blood coagulation inhibitors and antithrombotics)
 RN - 303134-06-7 CAPLUS
 CN - Benzamide, N-(2-aminophenyl)-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



@ HC1

RN 303134-17-0 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[[[2-aminophenyl]amino]carbonyl]phenyl]hexahydro-, 1,1-dimethylethyl ester

BNSDOCTD: <XP_2248767A_1>

BEST AVAILABLE COPY